Schlüter Birgitta, Gerhards Roswitha, Strumberg Dirk, Voigtmann Rudolf
Marienhospital Herne, Medizinische Klinik III: Hämatologie und Onkologie, Klinikum der Ruhr-Universität Bochum, Hölkeskampring 40, 44625, Herne, Germany.
J Cancer Res Clin Oncol. 2010 Sep;136(9):1389-400. doi: 10.1007/s00432-010-0790-2. Epub 2010 Mar 9.
PURPOSE: Her2/neu protein overexpression and gene amplification is found in 20-30% of breast cancer patients and correlates with poor clinical outcome. Patients who profit from anti-Her2/neu- therapy are routinely selected by examination of tumour specimens using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) separately. Many studies found a good correlation between both methods for score 1+ samples and for score 3+ samples, but not for score 2+ samples. In this study, we examined pleural and ascitic effusions with a combined approach using IHC and FISH on the same cells, under the following aspects: (1) frequency of Her2/neu protein expression and gene amplification in effusions; (2) correlation between score of protein expression and gene amplification; (3) impact of chromosome 17 polyploidy on Her2/neu protein expression. METHODS: We examined 31 effusions from patients with breast cancer and 4 effusions from patients with ovarian cancer. Cytospins were analysed by IHC using two anti-Her2/neu antibodies and subsequently analysed by FISH with Her2/neu/CEP17 probes. Amplification was defined as: (1) Her2/neu gene copy number of more than 4 and (2) Her2/neu/CEP17 ratio of 2.0 or greater. RESULTS: A system combining IHC and FISH was developed and 35 effusion specimens were examined. As much as 25 of them were scored as positive. All of them contained cells with heterogeneous scores. A total of 18 of the samples contained cells with scores that ranged from 0 to 3+. In the other samples scores ranged from 0 to 1+ or 0 to 2+. Cells were analysed for Her2/neu gene amplification and chromosome 17 ploidy with regard to their scores. As much as 15 of all samples had mean Her2/neu copy numbers of >4, but only 12% (n = 3) of the positive samples were amplified according to Her2/neu/CEP17 ratio. Only 22, 9% (n = 8) were polyploid (mean CEP17 > 4); but 65, 7% (n = 23) of all specimens contained single polyploid cells. In some cases up to 100% of the score 3+ cells showed chromosome 17 polyploidy. Here protein overexpression might be caused by polyploidy rather than by gene amplification. In some samples, we found single cells with gene amplification but without protein expression and cells without amplification but with protein overexpression. CONCLUSION: The combination of IHC and FISH allows a differentiated analysis of single cells, which is especially important for effusions that are composed of heterogeneous cells. Therefore, cells with high gene amplification and/or protein overexpression can be detected and analysed even if their amount in the sample is small. Chromosome 17 polyploidy is important in some cases but this should be further examined on a larger series.
目的:在20%-30%的乳腺癌患者中发现Her2/neu蛋白过表达和基因扩增,且与不良临床预后相关。常规通过分别使用免疫组织化学(IHC)和荧光原位杂交(FISH)检测肿瘤标本,来筛选能从抗Her2/neu治疗中获益的患者。许多研究发现,对于1+评分和3+评分的样本,两种方法之间具有良好的相关性,但对于2+评分的样本则不然。在本研究中,我们采用IHC和FISH相结合的方法,在相同细胞上从以下几个方面对胸腔积液和腹水进行了检测:(1)积液中Her2/neu蛋白表达和基因扩增的频率;(2)蛋白表达评分与基因扩增之间的相关性;(3)17号染色体多倍体对Her2/neu蛋白表达的影响。 方法:我们检测了31例乳腺癌患者的积液和4例卵巢癌患者的积液。通过使用两种抗Her2/neu抗体的IHC分析细胞涂片,随后用Her2/neu/CEP17探针进行FISH分析。扩增的定义为:(1)Her2/neu基因拷贝数超过4;(2)Her2/neu/CEP17比值为2.0或更高。 结果:开发了一种将IHC和FISH相结合的系统,并检测了35份积液标本。其中多达25份被评为阳性。所有阳性标本均含有评分各异的细胞。共有18个样本中的细胞评分范围为0至3+。在其他样本中,评分范围为0至1+或0至2+。根据细胞评分对Her2/neu基因扩增和17号染色体多倍体进行分析。所有样本中多达15个样本的Her2/neu平均拷贝数>4,但根据Her2/neu/CEP17比值,只有12%(n = 3)的阳性样本发生了扩增。只有22.9%(n = 8)为多倍体(平均CEP17>4);但所有标本中有65.7%(n =
Health Technol Assess. 2001
Cochrane Database Syst Rev. 2018-2-6
Health Technol Assess. 2006-9
Cochrane Database Syst Rev. 2016-3-1
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2022-3-2
Cytojournal. 2021-12-6
Pleura Peritoneum. 2016-3-1
Onco Targets Ther. 2014-7-31
Appl Immunohistochem Mol Morphol. 2007-9
J Histochem Cytochem. 2007-1
Breast Cancer. 2006
Eur J Clin Invest. 2006-8